This meta-analysis compares anti-EGFR (cetuximab, panitumumab) therapies to anti-VEGF (bevacizumab) therapies when combined with FOLFIRI or FOLFOX chemotherapy, as first-line treatment for advanced or metastatic colorectal cancer. Here, EGFR is linked to metastatic colorectal cancer.